FDG-PET/CT bzw. FDG-PET/MRT als integraler Bestandteil der Therapiesteuerung beim pädiatrischen Hodgkin-Lymphom

Zusammenfassung

Die FDG-PET ist seit 2007 fester Bestandteil in der Therapie des pädiatrischen Hodgkin-Lymphoms (PHL) und spielt sowohl bei der Stadien-Festlegung als auch für die Frühresponse-Evaluation eine zentrale Rolle. Der aktuelle Artikel ordnet die FDG-PET in den Gesamtkontext der Behandlung des PHL ein und fasst die wichtigsten aktuellen Änderungen, die bez. des Einsatzes der PET im europäischen Therapie-Optimierungskonzept vorgenommen werden, zusammen.

Abstract

FDG-PET plays an essential role in treatment tailoring of paediatric Hodgkin’s lymphoma. The current paper describes how FDG-PET is integrated in both the initial staging and the early res­ponse assessment and depicts methodological innovations regarding the favoured imaging protocols and algorithms for response assessment.

Schlüsselwörter

FDG-PET/CT - FDG-PET/MRT - pädiatrisches Hodgkin-Lymphom - EuroNet-Studienprotokolle - Untersuchungsprotokolle - qPET

Key words

FDG-PET/CT - FDG-PET/MRT - paediatric Hodgkin’s ­lymphoma - EuroNet-trials - imaging protocols - qPET

• Literatur

• 1 Bhatia S, Yasui Y, Robison LL et al. High rish of subsequent neoplasm continues with extened follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncology 2003; 21: 4386-4394
• 2 Dörffel W, Rühl U, Lüders H et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. JCO 2013; 31: 1562-1568
• 3 Gollub MJ, Hong R, Sarasohn DM et al. Limitations of CT during PET/CT. JNM 2007; 48: 1583-1591
• 4 Hasenclever D, Kurch L, Mauz-Körholz C et al. qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging 2014; 41: 1301-1308
• 5 Körholz D, Kluge R, Wickmann C et al. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin’s lymphoma in childhood and adolescence – consequences for the GPOH-HD-2003 protocol. Onkologie 2003; 26: 489-493
• 6 Juweid ME, Stroobants S, Hoekstra OS et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the imaging subcomittee of International Harmonization Project in Lymphoma. JCO 2007; 25: 571-578
• 7 Kluge R, Körholz D. Die Bedeutung der FDG-PET für die Stadieneinteilung und Therapie des Hodgkin-Lymphoms im Kindesalter. Klinische Pädiatrie 2011; 223: 315-319
• 8 Kluge R, Kurch L, Montravers F et al. FDG PET/CT in children and adolescents with lymphoma. Pediatric Radiology 2013; 43: 406-417
• 9 Kurch L, Sabri O, Kluge R. Die Rolle der FDG-PET/CT bei malignen Lymphomen im Kindes- und Jugendalter unter besonderer Berücksichtigung des Hodgkin-Lymphoms. Der Nuklearmediziner 2013; 36: 96-106
• 10 Kurch L, Mauz-Körholz C, Bertling S et al. The EuroNet paediatric hodgkin network – modern imaging data management for real time central review in multicentre trials. Klinische Pädiatrie 2013; 225: 357-361
• 11 Körholz D, Claviez A, Hasenclever D. et al. The concept of the GPOH-HD-2003 therapy study for pediatric Hodgkin’s disease: Evolution in the tradition of the DAL/GPOH studie. Klinische Pädiatrie 2004; 216: 150-156
• 12 Mathews JD, Forsythe AV, Brady Z et al. Cancer risk in 680.000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australian. BMJ 2013; 346: 2360-2377
• 13 Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D et al. Resection alone in 58 children with limited stage, Lymphocyte-predominant Hodgkin Lymphoma – Experience from the European Network Group on Pediatric Hodgkin Lymphoma. Cancer 2007; 110: 179-185
• 14 McCarten KM, Metzger M, Drachtman RI et al. Pleural effusions in intermediate risk Hodgkin Lymphoma: Evolution and Significance (Abstract O100). Pediatr Radiol 2014; 44 (Suppl. 02) 334
• 15 Meignan M. Interim PET in lymphoma: A step towards standardiza­tion. EJNM 2010; 37: 1821-1823
• 16 Miglioretti DL, Johnson E, Williams A et al. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr 2013; 167: 700-707
• 17 Pellegrino B, Terrier-Lacombe MJ, Oberlin O et al. Lymphocyte-predominant Hodgkin’s lymphoma in children: Therapeutic abstention after initial lymph node resection – A study of the French Society of Pediatic Oncology. JCO 2003; 21: 2948-2952
• 18 Purz S, Mauz-Körholz C, Körholz D et al. 18F-Fluorodesoxyglucose Positron Emission Tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. JCO 2011; 29: 3523-3528
• 19 Rodriguez-Vigil B, Gomenz-Leon N, Pinilla I et al. PET/CT in lymphoma: prospective study of enhanced full dose PET/CT versus unenhanced low-dose PET/CT. JNM 2006; 47: 1643-1648
• 20 Rühl U, Albrecht M, Dieckmann K et al. Response-adapted radiotherapy in the treatment of pediatic Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD95 trial. Int J Rad Oncol Biol Phys 2001; 51: 1209-1218
• 21 Schaefer NG, Hany TF, Taverna C et al. Non-Hodgkin-lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging – do we need contrast-enhanced CT?. Radiology 2004; 232: 823-829